BRIEF-Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy

Senti Biosciences Holdings Inc

Senti Biosciences Holdings Inc

SNTI

0.00

May 14 (Reuters) - Senti Biosciences Holdings Inc SNTI.O:

  • SENTI BIOSCIENCES HOLDINGS ANNOUNCES POSITIVE FDA RMAT MEETING ON REGISTRATIONAL CLINICAL AND CMC STRATEGY FOR SENTI-202 IN RELAPSED/REFRACTORY AML, ALONG WITH IMPORTANT EFFICACY AND DURABILITY UPDATES ON THE SENTI-202 CLINICAL PROGRAM

  • SENTI BIOSCIENCES HOLDINGS INC - TO INITIATE SINGLE-ARM MULTI-CENTER REGISTRATION TRIAL FOR SENTI-202 IN R/R AML

  • SENTI BIOSCIENCES HOLDINGS INC - SENTI-202 FUTURE MANUFACTURING TO USE DONOR X PHENOTYPE

Source text: ID:nGNX36HSqF

Further company coverage: SNTI.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.